Year : 2014  |  Volume : 16  |  Issue : 3  |  Page : 354-358

Glucocorticoids and prostate cancer treatment: friend or foe?

1 Department of Medicine, University of Washington, Seattle, Washington, USA
2 Seattle Cancer Care Alliance, Seattle, Washington, USA
3 Department of Medicine, University of Washington, Seattle; Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Correspondence Address:
Bruce Montgomery
Department of Medicine, University of Washington, Seattle, Washington
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1008-682X.125392

Rights and Permissions

Glucocorticoids have been used in the treatment of prostate cancer to slow disease progression, improve pain control and offset side effects of chemo- and hormonal therapy. However, they may also have the potential to drive prostate cancer growth via mutated androgen receptors or glucocorticoid receptors (GRs). In this review we examine historical and contemporary use of glucocorticoids in the treatment of prostate cancer, review potential mechanisms by which they may inhibit or drive prostate cancer growth, and describe potential means of defining their contribution to the biology of prostate cancer.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded731    
    Comments [Add]    
    Cited by others 23    

Recommend this journal